Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial

How Long? the just Continuation of empirical antimicrobial therapy (EAT) for febrile neutropenia in patients with haematological malignancies until neutrophil recovery could prolong the therapy innecessarily. We did an investigator-driven, superiority, open-label, randomised, controlled phase 4 clinical trial in six hospitals in Spain. For the experimental group, EAT was withdrawn after 72 h or more…